IL-17 in rheumatoid arthritis: A new target for treatment or just another cytokine?

Joint Bone Spine

Volumn 71, Issue 2, 2004, Pages 87-90

  Miossec, Pierre ^a  

^a EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

Bone resorption; Cytokines; IL 1; IL 17; Inflammation; TNF

Indexed keywords

CYTOKINE; INTERLEUKIN 1; INTERLEUKIN 17; TUMOR NECROSIS FACTOR ALPHA;

BONE MARROW; EDITORIAL; NONHUMAN; OSTEOBLAST; RHEUMATOID ARTHRITIS; SYNOVIOCYTE; SYNOVIUM; T LYMPHOCYTE;

ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; CYTOKINES; FEMALE; HUMANS; INTERLEUKIN-17; MALE; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX;

EID: 1642503128     PISSN: 1297319X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbspin.2003.06.001     Document Type: Editorial

References (37)

1. Yao Z., Painter S.L., Fanslow W.C., Ulrich D., Macduff B.M., Spriggs M.K., et al. Human IL-17: a novel cytokine derived from T cells. J Immunol. 155:1995;5483-5486.
2. Fossiez F., Djossou O., Chomarat P., Flores-Romo L., Ait-Yahia S., Maat C., et al. T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. J Exp Med. 183:1996;2593-2603.
3. Firestein G.S. Evolving concepts of rheumatoid arthritis. Nature. 423:(6937):2003;356-361.
4. Miossec P. Interleukin-17 in rheumatoid arthritis: if T cells were to contribute to inflammation and destruction through synergy. Arthritis Rheum. 48:2003;594-601.
5. Aggarwal S., Gurney A.L. IL-17: prototype member of an emerging cytokine family. J Leukoc Biol. 71:2002;1-8.
6. Starnes T., Broxmeyer H.E., Robertson M.J., Hromas R. Cutting edge: IL-17D, a novel member of the IL-17 family, stimulates cytokine production and inhibits hemopoiesis. J Immunol. 169:2002;642-646.
7. Hurst S.D., Muchamuel T., Gorman D.M., Gilbert J.M., Clifford T., Kwan S., et al. New IL-17 family members promote Th1 or Th2 responses in the lung: in vivo function of the novel cytokine IL-25. J Immunol. 169:2002;443-453.
8. Moseley T.A., Haudenschild D.R., Rose L., Reddi A.H. Interleukin-17 family and IL-17 receptors. Cytokine Growth Factor Rev. 14:2003;155-174.
9. Yao Z., Fanslow W.C., Seldin M.F., Rousseau A.M., Painter S.L., Comeau M.R., et al. Herpesvirus Saimiri encodes a new cytokine, IL-17, which binds to a novel cytokine receptor. Immunity. 3:1995;811-821.
10. Yao Z., Spriggs M.K., Derry J.M., Strockbine L., Park L.S., VandenBos T., et al. Molecular characterization of the human interleukin (IL)-17 receptor. Cytokine. 9:1997;794-800.
11. Kehlen A., Thiele K., Riemann D., Langner J. Expression, modulation and signalling of IL-17 receptor in fibroblast-like synoviocytes of patients with rheumatoid arthritis. Clin Exp Immunol. 127:2002;539-546.
12. Shalom-Barak T., Quach J., Lotz M. Interleukin-17-induced gene expression in articular chondrocytes is associated with activation of mitogen-activated protein kinases and NF-kappaB. J Biol Chem. 273:1998;27467-27473.
13. Chevrel G., Page G., Granet C., Streichenberger N., Varennes A., Miossec P. Interleukin-17 increases the effects of IL-1beta on muscle cells: arguments for the role of T cells in the pathogenesis of myositis. J Neuroimmunol. 137:2003;125-133.
14. Miossec P., van den Berg W. Th1/Th2 cytokine balance in arthritis. Arthritis Rheum. 40:1997;2105-2115.
15. Aarvak T., Chabaud M., Miossec P., Natvig J.B. IL-17 is produced by some proinflammatory Th1/Th0 cells but not by Th2 cells. J Immunol. 162:1999;1246-1251.
16. Chabaud M., Aarvak T., Garnero P., Natvig J.B., Miossec P. Potential contribution of IL-17-producing Th1 cells to defective repair activity in joint inflammation: partial correction with Th2 promoting conditions. Cytokine. 13:2001;113-118.
17. Chabaud M., Fossiez F., Taupin J.L., Miossec P. Enhancing effect of IL-17 on IL-1-induced IL-6 and leukemia inhibitory factor production by rheumatoid arthritis synoviocytes and its regulation by Th2 cytokines. J Immunol. 161:1998;409-414.
18. Katz Y., Nadiv O., Beer Y. Interleukin-17 enhances tumor necrosis factor alpha-induced synthesis of interleukins 1, 6, and 8 in skin and synovial fibroblasts: a possible role as a "fine-tuning cytokine" in inflammation processes. Arthritis Rheum. 44:2001;2176-2184.
19. Martel-Pelletier J., Mineau F., Jovanovic D., Di Battista J.A., Pelletier J.P. Mitogen-activated protein kinase and nuclear factor kappaB together regulate interleukin-17-induced nitric oxide production in human osteoarthritic chondrocytes: possible role of transactivating factor mitogen-activated protein kinase-activated protein kinase (MAPKAPK). Arthritis Rheum. 42:1999;2399-2409.
20. LeGrand A., Fermor B., Fink C., Pisetsky D.S., Weinberg J.B., Vail T.P., et al. Interleukin-1, tumor necrosis factor alpha, and interleukin-17 synergistically up-regulate nitric oxide and prostaglandin E2 production in explants of human osteoarthritic knee menisci. Arthritis Rheum. 44:2001;2078-2083.
21. Van bezooijen R.L., Farih-Sips H.C., Papapoulos S.E., Lowik C.W. Interleukin-17: a new bone acting cytokine in vitro. J Bone Miner Res. 14:1999;1513-1521.
22. Kotake S., Udagawa N., Takahashi N., Matsuzaki K., Itoh K., Ishiyama S., et al. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest. 103:1999;1345-1352.
23. Chabaud M., Garnero P., Dayer J.M., Guerne P.A., Fossiez F., Miossec P. Contribution of interleukin 17 to synovium matrix destruction in rheumatoid arthritis. Cytokine. 12:2000;1092-1099.
24. Chabaud M., Page G., Miossec P. Enhancing effect of IL-1, IL-17, and TNF-alpha on macrophage inflammatory protein-3alpha production in rheumatoid arthritis: regulation by soluble receptors and Th2 cytokines. J Immunol. 167:2001;6015-6020.
25. Attur M.G., Patel R.N., Abramson S.B., Amin A.R. Interleukin-17 up-regulation of nitric oxide production in human osteoarthritis cartilage. Arthritis Rheum. 40:1997;1050-1053.
26. Cai L., Yin J.P., Starovasnik M.A., Hogue D.A., Hillan K.J., Mort J.S., et al. Pathways by which interleukin 17 induces articular cartilage breakdown in vitro and in vivo. Cytokine. 16:2001;10-21.
27. Chabaud M., Lubberts E., Joosten L., van Den Berg W., Miossec P. IL-17 derived from juxta-articular bone and synovium contributes to joint degradation in rheumatoid arthritis. Arthritis Res. 3:2001;168-177.
28. Lubberts E., Joosten L.A., van de Loo F.A., van den Gersselaar L.A., van den Berg W.B. Reduction of interleukin-17-induced inhibition of chondrocyte proteoglycan synthesis in intact murine articular cartilage by interleukin-4. Arthritis Rheum. 43:2000;1300-1306.
29. Lubberts E., Joosten L.A., Oppers B., van den Bersselaar L., Coenen-de Roo C.J., Kolls J.K., et al. IL-1-independent role of IL-17 in synovial inflammation and joint destruction during collagen-induced arthritis. J Immunol. 167:2001;1004-1013.
30. Lubberts E., Joosten L.A., van de Loo F.A., Schwarzenberger P., Kolls J., van den Berg W.B. Overexpression of IL-17 in the knee joint of collagen type II immunized mice promotes collagen arthritis and aggravates joint destruction. Inflamm Res. 51:2002;102-104.
31. Rifas L., Avioli L.V. A novel T cell cytokine stimulates interleukin-6 in human osteoblastic cells. J Bone Miner Res. 14:1999;1096-1103.
32. Nakashima T., Kobayashi Y., Yamasaki S., Kawakami A., Eguchi K., Sasaki H., et al. Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-kappaB ligand: modulation of the expression by osteotropic factors and cytokines. Biochem Biophys Res Commun. 275:2000;768-775.
33. Romas E., Gillespie M.T., Martin T.J. Involvement of receptor activator of NFkappaB ligand and tumor necrosis factor-alpha in bone destruction in rheumatoid arthritis. Bone. 30:2002;340-346.
34. Bush K.A., Farmer K.M., Walker J.S., Kirkham B.W. Reduction of joint inflammation and bone erosion in rat adjuvant arthritis by treatment with interleukin-17 receptor IgG1 Fc fusion protein. Arthritis Rheum. 46:2002;802-805.
35. Chabaud M., Miossec P. The combination of tumor necrosis factor alpha blockade with interleukin-1 and interleukin-17 blockade is more effective for controlling synovial inflammation and bone resorption in an ex vivo model. Arthritis Rheum. 44:2001;1293-1303.
36. Lubberts E., Joosten L.A., Chabaud M., van Den Bersselaar L., Oppers B., Coenen-De Roo C.J., et al. IL-4 gene therapy for collagen arthritis suppresses synovial IL-17 and osteoprotegerin ligand and prevents bone erosion. J Clin Invest. 105:2000;1697-1710.
37. Benchetrit F., Ciree A., Vives V., Warnier G., Gey A., Sautes-Fridman C., et al. Interleukin-17 inhibits tumor cell growth by means of a T-cell-dependent mechanism. Blood. 99:2002;2114-2121.